The Effects of Green Tea and Salvadora Persica L. in Patients With Gingivitis

NCT ID: NCT06211309

Last Updated: 2024-01-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE2

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-01-01

Study Completion Date

2024-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gingivitis is an inflammatory condition of the gingival tissue, most commonly caused by bacterial infection.The plaque control is considered the most important preventive factor concerning caries, gingivitis, and periodontitis Mechanical means of plaque control, e.g. tooth brushing, flossing and use of other mechanical devices are the most commonly used methods. However, ideal plaque control solely by mechanical means requires a significant effort and is difficult to achieve.This has led to the introduction of chemical methods of plaque control using antimicrobial agentsMore specifically, chemotherapeutic agents with antimicrobial properties, such as 0.12% chlorhexidine (CHX).chx has side effects encourage the need to develop alternative mouthwashes with similar efficacy but without these issues.hence the mouthwash enriched with a combination of aqueous extracts of Salvadora persica L. and green tea used as a substitution to CHX with minimal side effects .The objective of this study was to investigate the efficacy of the combination of Gt aqueous extract and Sp aqueous extract in reducing plaque buildup and gingivitis for 4 weeks duration.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Gingivitis is an inflammatory condition of the gingival tissue, most commonly caused by bacterial infection. Unlike periodontitis, there is no attachment loss and therefore no migration of the junctional epithelium. The condition is restricted to the soft-tissue area of the gingival epithelium and connective tissue.Gingivitis is caused by the microbial plaque deposits located in or close to the gingival sulcus).

The plaque control is considered the most important preventive factor concerning caries, gingivitis, and periodontitis Mechanical means of plaque control, e.g. tooth brushing, flossing and use of other mechanical devices are the most commonly used methods. However, ideal plaque control solely by mechanical means requires a significant effort and is difficult to achieve.This has led to the introduction of chemical methods of plaque control using antimicrobial agentsMore specifically, chemotherapeutic agents with antimicrobial properties, such as 0.12% chlorhexidine (CHX), have been proposed as an adjunct to the standard oral hygiene protocol. chx has side effects encourage the need to develop alternative mouthwashes with similar efficacy but without these issues.

Hence the mouthwash enriched with a combination of aqueous extracts of Salvadora persica L. and green tea used as a substitution to CHX with minimal side effects .

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gingivitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

co.mouthwash

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Group Type ACTIVE_COMPARATOR

co.mouthwas

Intervention Type DRUG

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Kin mouthwash

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Group Type PLACEBO_COMPARATOR

Kin

Intervention Type OTHER

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Distilled water

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Group Type PLACEBO_COMPARATOR

Distilled water

Intervention Type OTHER

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

co.mouthwas

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Intervention Type DRUG

Kin

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Intervention Type OTHER

Distilled water

15ml twice a day, rinse for 30sec refrain from eating or drinking for 30min

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

co

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Subjects aged more than 15 years-old who will volunteer to participate.
2. Participants who were apparently systemically healthy.
3. Not taking antibiotic and anti-inflammatory drugs in the last three months
4. Patients having generalized gingivitis with intact periodontium in which they have more than 30% bleeding sites with no PPD \>3 mm with no clinical attachment loss according to criteria proposed by

Exclusion Criteria

1. Those with history of systemic chronic disease, immunocompromised patients.
2. Those currently using any mouthwash.
3. Those on antibiotic therapy, anti-inflammatory medications or NSAID during the study and at the last 3 months before the study.
4. Those having a history of hypersensitivity to any product used in the present study.
5. Those having periodontitis.
6. Those who smoker or alcoholism.
7. handicapped patient or patients with limited manual dexterities.
8. pregnant , lactating women or taking contraceptive pills.
9. Subjects wearing orthodontic appliances or removable dentures.
10. patients unwilling to participate in study.
Minimum Eligible Age

15 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Baghdad

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Aliaa Saeed Salman

principal investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Aliaa

Baghdad, , Iraq

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Iraq

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Aliaa saeed salman, master

Role: primary

0771 581 4202 ext. 0096

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

857623

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Miswak Efficacy Compared With Chlorhexidine
NCT04607785 COMPLETED EARLY_PHASE1